Skip to Content

'
Ana M. Gonzalez-Angulo, M.D., M.Sc., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007 The University of Texas Health Science Center, Houston, TX, M.Sc., Translational Research Sciences
1995 Universidad del Cauca School of Medicine, Popayan, Colombia, MD, Physician and Surgeon

Postgraduate Training

7/2003-6/2004 Fellow, Susan G. Komen Interdisciplinary Breast Cancer, UT M.D. Anderson Cancer Center, Houston, TX, Gabriel N. Hortobagyi, M.D.
7/2001-6/2003 Fellow, Medical Oncology, Ochsner Clinic Foundation, New Orleans, LA, John T. Cole, M.D.
7/1999-6/2001 Resident, Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, Gloria B. Weinberg, M.D.
6/1998-6/1999 Intern, Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, Gloria B. Weinberg, M.D.

Board Certifications

11/2003 ABIM-Diplomat, Medical Oncology
8/2001 ABIM-Diplomat, Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2004-8/2009
Assistant Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2004-8/2009

Selected Publications

Peer-Reviewed Original Research Articles
1. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault R, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncol. e-Pub 7/2009.
2. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Tranina TA, Hudis C, Hortobagyi GN, Gerlad WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15(7):2472-8, 4/1/2009. e-Pub 3/10/2009. PMID: 19276248.
3. Litton JK, Westin SK, Ready K, Sun CC, Peterson S, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu K, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/15/2009. PMID: 19280625.
4. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 50(2):231-8, 2/2009. e-Pub 1/21/2009. PMID: 19164229.
5. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4). e-Pub 1/15/2009. PMID: 19150943.
6. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M.. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20:1013-1019, 2009. PMID: 19237480.
7. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530 resistant tumors. Clin Cancer Res 15:3396-3405, 2009.
8. Agarwal R, Gonzalez-Angulo AM (Joint 1st author), Myhre S, Carey MS, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15:3654-3662, 2009.
9. Jirlerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009.
10. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin CT, Yang WT, Hennessy BTJ, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27(2):220-226, 2009. e-Pub 12/1/2008. PMID: 19047281.
11. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 7/2008. PMID: 18334512.
12. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol, 7/2008. PMID: 18667396.
13. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory Breast Cancer - PET/CT, MRI, Mammography, and Sonography Findings. Breast Cancer Res Treat 109(3):417-26, Nov-Dec, 6/2008. PMID: 17653852.
14. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Gonzalez-Angulo AM. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112(9):1905-11, Nov-Dec, 5/1/2008. PMID: 18300243.
15. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M. Prognostic value of Body Mass Index (BMI) in Locally Advanced Breast Cancer (LABC). Clin Cancer Res 14(6):1718-25, Nov-Dec, 3/2008. PMID: 18347172.
16. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. The combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246-52, Nov-Dec, 1/2008. PMID: 18056680.
17. Stemke-Hale K, Gonzalez-Angulo AM (Joint 1st author), Lluch A, Neve R, Kuo WL, Davies M, Carey M, Hu Z, GuanY, Sahin A, Symmans WF, Pusztai L, Nolden L, Horlings H, Berns K, Hung MC, van de Vijver M, Valero V, Gray J, Bernards R, Mills G, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008.
18. Atchley D, Albarracin C, Lopez A, Valero V, Amos C, Gonzalez-Angulo AM, Hortobagyi G, Arun B. Clinical and Pathological Characteristics of BRCA-Positive and BRCA-Negative Breast Cancer Patients. J Clin Oncol 26:4482-4488, 2008.
19. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: The M.D. Anderson Experience. Ann Surg Oncol 15(1):244-249, Nov-Dec, 2008. PMID: 18043978.
20. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo AM, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782-8, 2008.
21. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108(2):183-190, Nov-Dec, 2008. PMID: 17468948.
22. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic Value of Initial Clinical Disease Stage after achieving Pathological Complete Response. Oncologist 13(1):6-15, Nov-Dec, 2008. PMID: 18245008.
23. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 10(8):1275-1281, Nov-Dec, 2008. PMID: 18250347.
24. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin A, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging to define outcomes for breast cancer after neoadjuvant therapy. Cancer Res 68:6477-81, 2008.
25. Litton JK, Gonzalez-Angulo AM, Warneke C, Buzdar AU, Kau S, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. The relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26:4072-4077, 2008.
26. Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER-2 status. Clin Breast Cancer 8:366-369, 2008.
27. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in Survival over the Past Two Decades among White and Black Patients with De Novo Stage IV Breast Cancer. J Clin Oncol 26:4899-4905, 2008.
28. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar A, Hortobagyi GN. Using response to primary chemotherapy to select the postoperative therapy: long term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer 8:516-521, 2008.
29. Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7(11):867-74, Nov-Dec, 12/2007. PMID: 18269777.
30. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25(31):4952-60, 11/1/2007. PMID: 17971593.
31. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 10/1/2007. PMID: 17676585.
32. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110(6):1195-200, 9/15/2007. PMID: 17647266.
33. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low local-regional failure rates in selected breast cancer patients with tumor positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723-30, 8/2007. PMID: 17587208.
34. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Post-mastectomy radiation improves the outcome of patients with stage III breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-9, 7/2007. PMID: 17418973.
35. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-5, 7/2007. PMID: 17602071.
36. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402, 2007. PMID: 17936563.
37. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, De La Garza JG. Adjuvant Chemotherapy with Doxorubicin and Dacarbazine Has No Effect in Recurrence-Free Survival of Malignant Phyllodes Tumors of the Breast. Breast J 13(6):551-556, Nov-Dec, 2007. PMID: 17983394.
38. Gonzalez-Angulo AM. Advances in Triple Receptor-negative Breast Cancer. Clin Adv Hematol Oncol 5(12):956-957, Nov-Dec, 2007. PMID: 18277956.
39. Hennessy BT, Gilcrease MZ, Kim E, Gonzalez-Angulo AM. Breast Carcinoma with Neuroendocrine Differentiation and Myocardial Metastases. Clin Breast Cancer 7(11):892-4, Nov-Dec, 2007. PMID: 18269781.
40. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18:1021-1029, 2007.
41. Mazouni C, Kau SW, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18:874-880, 2007.
42. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436-1444, 2007. PMID: 17694554.
43. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22, 2007.
44. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421-7431, Nov-Dec, 2007. PMID: 18094426.
45. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Primary Angiosarcomas of the Breast. Cancer 110(1):173-178, 2007. PMID: 17541936.
46. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: Is survival improving? Oncologist 12(8):904-12, 2007. PMID: 17766649.
47. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7(5):396-400, 12/2006. PMID: 17239264.
48. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer 7(4):326-30, 10/2006. PMID: 17092400.
49. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11(8):857-67, 9/2006. PMID: 16951389.
50. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107-15, 9/2006. PMID: 16908934.
51. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 60:61-67, 9/2006. PMID: 17009032.
52. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107(6):1248-54, 9/2006. PMID: 16862596.
53. Reddy B, Gonzalez-Angulo AM, Kemmerly SA. Splenic vein thrombosis presenting as Fusobacterium nucleatum bacteremia. J La State Med Soc 158(4):183-5, 7/2006. PMID: 17022361.
54. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24(13):2113-22, 5/2006. PMID: 16648513.
55. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-44, 3/1/2006. PMID: 16505422.
56. Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M. Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17:813-7, 2006.
57. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, Fornage B, Singletary SE, Sahin A, Buzdar AU, Valero V. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106(5):1000-6, 2006.
58. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. J Clin Oncol 23(33):8331-39, 11/2005. PMID: 16293864.
59. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-104, 10/2005. PMID: 16192593.
60. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466-72, 6/2005. PMID: 15852360.
61. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41-8, 2005. PMID: 15625359.
62. Gonzalez-Angulo AM, Walters RS, Carpenter RJ, Jr, Ross MI, Perkins GH, Gwyn K, Theriault RL. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 5(4):317-9, 10/2004. PMID: 15507181.
63. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 10(18 Pt 1):6215-21, 9/2004. PMID: 15448010.
64. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101(2):258-63, 7/2004. PMID: 15241821.
65. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 4(6):415-9, 2/2004. PMID: 15023242.
66. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101(10):1760-6, 2004. PMID: 15386311.
67. Resetkova E, Gonzalez-Angulo AM, Sneige N, McDonnell T, Buzdar AU, Kau SW, Yamamura Y, Reuben J, Hortobagyi GN and Cristofanilli M.. P53,mdm2 and muc1 expression as predictors of prognosis in inflammatory breast cancer. Cancer 101:913-7, 2004. PMID: 15329897.
68. Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy: A Case of Successful Retreatment with Ifosfamide without Encephalopathy. South Med J 95(10):1215-7, 10/2002. PMID: 12425514.

Grant & Contract Support

Title: Targeting the P13K Pathway in Women's Cancers
Funding Source: American Association for Cancer Research (AACR)
Role: Co-Investigator
Principal Investigator: Cantley, Mills, Sawyers
Duration: 9/1/2009 - 8/30/2012
 
Title: Chemotherapy Resistance in Hispanic and African American Patients
Funding Source: Komen for the Cure Catalystic Award for Disparities
Role: Principal Investigator
Duration: 8/1/2009 - 7/31/2012
 
Title: Developing Effective Therapies for ER-negative Breast Cancer using Genomics and Proteomics
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator (Years 3 and 4)
Principal Investigator: Brown
Duration: 5/22/2008 - 5/21/2013
 
Title: Implications of Targeted Therapies: Accurate Determination of Mutation Status
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Collaborator (Years 3 and 4)
Principal Investigator: Mills
Duration: 5/22/2008 - 5/21/2011
 
Title: A phase I-II, randomized open label clinical trial of fulvestrant versus the combination of fulvestrant and PI3K and Src pathways inhibitors as first-line therapy for metastatic hormone receptor-positive HER2-negative breast cancer
Funding Source: Commonwealth Foundation for Cancer Research
Role: Principal Investigator
Duration: 5/1/2008 - 4/30/2011
 
Title: Prospective Evaluation of Molecular Triaging with Pharmacogenomic Tests to Select Neoadjuvant Chemotherapy
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Collaborator
Principal Investigator: Symmans/Pusztai (Co-PIs)
Duration: 4/1/2008 - 3/31/2011
 
Title: Biomarkers Identification and Validation Award; Functional Proteomics-Based Breast Cancer Biomarkers
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Principal Investigator
Principal Investigator: Mills
Duration: 5/1/2007 - 4/30/2010
 
Title: The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2011
 
Title: The PI3K/PTEN/AKT Signal Transduction Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer (Runs as concurrent effort with 1K23CA121994-01.)
Funding Source: CDA ASCO
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2009

Last updated: 8/31/2009